Lactobacillus rhamnosus CCFM1119 (JS-SZ-2-1)

Anti-Helicobacter pylori

Daily dosage in clinical study

20 billion CFU for 4 weeks

 FUNCTIONALITY

Anti-Helicobacter pylori infection • Gut Microbiota Modulation

Human clinical trial

ZHANG., M, ZHAI Q., ZHAO J., ZHANG H., CHEN W., Clinical efficacy evaluation of Lactobacillus rhamnosus JS-SZ-2-1 against Helicobacter pylori infection. Food and Fermentation Industries, 2020.

Chinese Clinical Trial Registry : ChiCTR1900024938, Lactobacillus rhamnosus JS-SZ-2-1 can alleviative H pylori infection by reducing value of 14C-UBT (△UBT=106.00) and value of gastrointestinal symptom rating scale (GSRS) (P<0.05). Negative conversion ratio 61.54%

Why CCFM1119

• Helicobacter pylori ( pylori) infection is the main pathogenic factor of peptic ulcer, chronic gastritis, and even gastric cancer.
• The infection rate of pylori is more than 50% worldwide, and the infection rate of developing countries (70%-90%) is much higher than that of developed countries (25%-50%).
• Triple therapy and quadruple therapy are mainly used as the treatment of pyloriat home and abroad, but due to the widespread use of antibiotics, there are some problems such as drug resistance of H. pylori, adverse reactions during treatment, gastrointestinal dysfunction and so on.

APPLICATION

Lactobacillus rhamnosus CCFM1119 (JS-SZ-2-1) is ideal for capsules, tablets, and stick-packs.

+ More details are available upon request